Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 8—August 2015

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

Suzanne Tavitian, Jean-Marie Peron, Françoise Huguet, Nassim Kamar, Florence Abravanel, Odile Beyne-Rauzy, Lucie Oberic, Stanislas Faguer, Laurent Alric, Murielle Roussel, Clément Gaudin, Loïc Ysebaert, Anne Huynh, and Christian RecherComments to Author 
Author affiliations: Université Paul Sabatier, Toulouse (S. Tavitian, J.-M. Peron, O. Beyne-Rauzy, L. Alric, C. Gaudin, C. Recher); Institut Universitaire du Cancer, Toulouse, France (S. Tavitian, F. Huguet, O. Beyne-Rauzy, L. Oberic, M. Roussel, L. Ysebaert, A. Huynh, C. Recher); Centre Hospitalier Universitaire, Toulouse, France (J.-.M Peron, N. Kamar, F. Abravanel, S. Faguer, L. Alric, C. Gaudin)

Main Article

Table 1

Clinical characteristics of 26 patients subsequently diagnosed with hepatitis E and hematologic malignancy, University Hospital of Toulouse, France, 2003*

Characteristic Value Ribavirin
p value
Yes, n = 12 No, n = 14
Sex, M/F 17/9 (65/35) 7/5 10/4 0.40
Age, median y (range)†
59 (21–86)
55 (21–86)
63 (33–84)
Hematological malignancy
Acute leukemia 9 (34.6) 3 (25) 6 (42.8%) NA
Indolent NHL‡ 8 (26.9) 4 (33.5) 4 (28.6%) NA
Aggressive NHL§ 3 (15.3) 2 (1) 1 (7.2%) NA
Multiple myeloma 3 (11.6) 1 (8.5) 2 (14.3%) NA
3 (11.6)
2 (17)
1 (7.2%)
SCT before or concomitant to hepatitis E
Allogenetic SCT
Hepatitis E
Serology, n = 23
IgM+ IgG+ 6 (26.1) 2 (16.7) 4 (28.6%) NA
IgM– IgG+ 3 (13) 1 (8.4) 2 (14.3%) NA
IgM+ IgG– 7 (30.5) 3 (25) 4 (28.6%) NA
IgM– IgG–
7 (30.5)
4 (33.5)
3 (21.5%)
At onset
AST, IU/L (range) 150 (17–2,309) 92 (17–1,688) 179 (20–2,309) 0.30
ALT, IU/L (range) 293 (24–4,273) 297 (24–2,189) 278 (47–4,273) 0.74
γGT, IU/L (range) 202 (18–1,665) 220 (50–1,665) 181 (18–492) 0.70
Bilirubin, μmol/L (range)
13 (6.3–107)
16 (6.3–107)
13 (7.7–88)
At month 6
AST, IU/L (range) 51 (14–1,127) 19.5 (14–325) 86 (38–1,127) 0.03
ALT, IU/L (range) 50 (10–1,523) 14 (10–446) 133 (39–1,523) 0.01
γGT, IU/L (range) 101 (14–1,375) 28 (14–1,375) 135 (34–671) 0.07
Bilirubin, μmol/L (range) 18 (6.1–2,61) 18 (7.4–261) 12 (6.1–37) 0.41

*Values are no. (%) patients except as indicated. NA, not applicable; NHL, non-Hodgkin lymphoma; SCT, stem cell transplant; AST, aspartate aminotransferase; ALT,alanine aminotransferase; γGT, gamma-glutamyl transferase.
†Age at diagnosis of HEV infection.
‡Indolent B cell lymphoma: follicular lymphoma (n = 2).
§Aggressive non-Hodgkin lymphoma: Burkitt-like B cell lymphoma (n = 1), anaplastic T-cell lymphoma (n = 1), Diffuse large B cell lymphoma (n = 2).
¶Others: myeloproliferative neoplasm (n = 1); granulocytic sarcoma (n = 1); myeloid variant of hypereosinophilia with FIP1L1-PDGFRα rearrangement. p value refers to comparison between patients who received ribavirin and patients who did not. Data from 6 patients of this cohort were previously reported in a preliminary study (6).

Main Article

  1. Kamar  N, Dalton  HR, Abravanel  F, Izopet  J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27:11638. DOIPubMedGoogle Scholar
  2. Hewitt  PE, Ijaz  S, Brailsford  SR, Brett  R, Dicks  S, Haywood  B, Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:176673.PubMedGoogle Scholar
  3. Kamar  N, Selves  J, Mansuy  J-M, Ouezzani  L, Péron  J-M, Guitard  J, Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:8117. DOIPubMedGoogle Scholar
  4. Dalton  HR, Keane  FE, Bendall  R, Mathew  J, Ijaz  S. Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med. 2011;155:47980. DOIPubMedGoogle Scholar
  5. Versluis  J, Pas  SD, Agteresch  HJ, de Man  RA, Maaskant  J, Schipper  MEI, Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:107986. DOIPubMedGoogle Scholar
  6. Tavitian  S, Péron  J-M, Huynh  A, Mansuy  J-M, Ysebaert  L, Huguet  F, Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol. 2010;49:1414. DOIPubMedGoogle Scholar
  7. Halac  U, Béland  K, Lapierre  P, Patey  N, Ward  P, Brassard  J, Cirrhosis due to chronic hepatitis E infection in a child post-bone marrow transplant. J Pediatr. 2012 May;160(5):871–4.e1.
  8. Pfefferle  S, Frickmann  H, Gabriel  M, Schmitz  N, Günther  S, Schmidt-Chanasit  J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2012;40:4514. DOIPubMedGoogle Scholar
  9. Guigonis  V, Dallocchio  A, Baudouin  V, Dehennault  M, Hachon-Le Camus  C, Afanetti  M, Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:126979. DOIPubMedGoogle Scholar
  10. Geng  Y, Zhang  H, Huang  W. J Harrison T, Geng K, Li Z, et al. Persistent hepatitis E virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon. 2014;14:e15618. DOIGoogle Scholar
  11. Kamar  N, Izopet  J, Tripon  S, Bismuth  M, Hillaire  S, Dumortier  J, Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:111120. DOIPubMedGoogle Scholar
  12. Kamar  N, Rostaing  L, Abravanel  F, Garrouste  C, Lhomme  S, Esposito  L, Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology. 2010;139:16128. DOIPubMedGoogle Scholar
  13. Woolson  KL, Forbes  A, Vine  L, Beynon  L, McElhinney  L, Panayi  V, Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther. 2014;40:128291.PubMedGoogle Scholar
  14. Mansuy  J-M, Huynh  A, Abravanel  F, Recher  C, Peron  JM, Izopet  J. Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. Clin Infect Dis. 2009;48:3734. DOIPubMedGoogle Scholar

Main Article

Page created: July 15, 2015
Page updated: July 15, 2015
Page reviewed: July 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.